Cingulate Inc.
Close on Oct 19, 2026
- Market cap
- $57.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 19, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | $-0.60 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | After market close | – | $-0.30 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | $-0.57 | – |
Press releases
Announcements Cingulate filed with the SEC
Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial
Results of operations · EX-99.1 to Form 8-K
Inc. (NASDAQ: CING) Added to Russell 3000E®
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Regulation FD disclosure · EX-99.1 to Form 8-K
Receives Complete Response Letter from FDA for CTx-1301
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety
Results of operations · EX-99.1 to Form 8-K
Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Results of operations · EX-99.1 to Form 8-K
Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Study Completed for Cingulate’s Lead Asset CTx-1301
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Completes Financing Transaction for Net Proceeds of $5,000,000
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results Reflecting
Results of operations · EX-99.1 to Form 8-K
Initiates Final Study for Lead ADHD Asset CTx-1301
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
Results of operations · EX-99.1 to Form 8-K
Cingulate Reports First Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Pricing of $7.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Closing of $7.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cingulate Controller Jennifer Callahan Promoted to CFO
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K
to Host CNS Key Opinion Leader Panel in New York City
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Successfully Manufactures Clinical Supply –
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Announces Successful Transfer of CTx-1301 (dexmethylphenidate)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
Results of operations · EX-99.1 to Form 8-K